Filing Flows › Sarepta Therapeutics (SRPT) › How it makes money
How Sarepta Therapeutics (SRPT) makes money
Sarepta Therapeutics (SRPT) made $381M of revenue in the third quarter 2026 (Q3 2026), -5% from a year earlier. Pmo Products brought in $240M (63%); Elevidys brought in $83.5M (22%); Other revenues brought in $57.6M (15%).
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Pmo Products | $240M | 63.0% | +4% | +0.7% |
| Elevidys | $83.5M | 21.9% | -15% | -37% |
| Other revenues | $57.6M | 15.1% | -21% | +96% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $381M | 100.0% |
| Income tax | $2.7M | 0.7% |
| Operating cash flow | $60.0M | 15.7% |
| Free cash flow | $57.0M | 15.0% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $381M | -4% |
| Q2 2026 | $401M | -34% |
| Q1 2026 | $731M | -2% |
| Q4 2025 | $443M | -33% |
| Q3 2025 | $399M | -14% |
| Q2 2025 | $611M | +68% |
| Q1 2025 | $745M | +80% |
From Sarepta Therapeutics' 10-Q filed Nov 5, 2026 (on EDGAR).
Questions
How does Sarepta Therapeutics make money?
Sarepta Therapeutics (SRPT) made $381M of revenue in the third quarter 2026 (Q3 2026), -5% from a year earlier. Pmo Products brought in $240M (63%); Elevidys brought in $83.5M (22%); Other revenues brought in $57.6M (15%).
What is Sarepta Therapeutics' biggest business?
Pmo Products: $240M in the third quarter 2026, 63% of revenue, +0.7% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.